 Connection
Timothy McKinsey to Cardiomegaly
This is a "connection" page, showing publications Timothy McKinsey has written about Cardiomegaly.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.549 |
|
|
|
-
Reid BG, Stratton MS, Bowers S, Cavasin MA, Demos-Davies KM, Susano I, McKinsey TA. Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging. J Mol Cell Cardiol. 2016 08; 97:106-13.
Score: 0.515
-
Ferguson BS, McKinsey TA. Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol. 2015 Jun; 83:14-20.
Score: 0.476
-
Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol. 2014 Jul 15; 307(2):H252-8.
Score: 0.450
-
Haldar SM, McKinsey TA. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol. 2014 Sep; 74:98-102.
Score: 0.450
-
Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, Bradner JE, McKinsey TA. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol. 2013 Oct; 63:175-9.
Score: 0.426
-
Ferguson BS, Harrison BC, Jeong MY, Reid BG, Wempe MF, Wagner FF, Holson EB, McKinsey TA. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2013 Jun 11; 110(24):9806-11.
Score: 0.421
-
Phan D, Stratton MS, Huynh QK, McKinsey TA. A novel protein kinase C target site in protein kinase D is phosphorylated in response to signals for cardiac hypertrophy. Biochem Biophys Res Commun. 2011 Jul 29; 411(2):335-41.
Score: 0.368
-
Monovich L, Koch KA, Burgis R, Osimboni E, Mann T, Wall D, Gao J, Feng Y, Vega RB, Turner BA, Hood DB, Law A, Papst PJ, Koditek D, Chapo JA, Reid BG, Melvin LS, Pagratis NC, McKinsey TA. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochim Biophys Acta. 2009 May; 1789(5):422-31.
Score: 0.317
-
McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007 Aug; 6(8):617-35.
Score: 0.281
-
McKinsey TA. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res. 2007 Mar 01; 73(4):667-77.
Score: 0.268
-
Bush EW, Hood DB, Papst PJ, Chapo JA, Minobe W, Bristow MR, Olson EN, McKinsey TA. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem. 2006 Nov 03; 281(44):33487-96.
Score: 0.264
-
Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp. 2006; 274:3-12; discussion 13-9, 152-5, 272-6.
Score: 0.252
-
Harrison BC, Roberts CR, Hood DB, Sweeney M, Gould JM, Bush EW, McKinsey TA. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol. 2004 Dec; 24(24):10636-49.
Score: 0.234
-
Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004 Oct; 24(19):8374-85.
Score: 0.231
-
Woulfe KC, Travers JG, McKinsey TA. A Phosphatase Anchor Weighs on the Heart. Circulation. 2020 09 08; 142(10):963-966.
Score: 0.174
-
McKinsey TA, Olson EN. Cardiac hypertrophy: sorting out the circuitry. Curr Opin Genet Dev. 1999 Jun; 9(3):267-74.
Score: 0.159
-
McKinsey TA, Vondriska TM, Wang Y. Epigenomic regulation of heart failure: integrating histone marks, long noncoding RNAs, and chromatin architecture. F1000Res. 2018; 7.
Score: 0.153
-
Blakeslee WW, Lin YH, Stratton MS, Tatman PD, Hu T, Ferguson BS, McKinsey TA. Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes. J Mol Cell Cardiol. 2017 11; 112:74-82.
Score: 0.141
-
Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, Huang Y, Zhang R, Sahadevan A, Lemieux ME, Brown JD, Srivastava D, Bradner JE, McKinsey TA, Haldar SM. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med. 2017 05 17; 9(390).
Score: 0.138
-
Lin YH, Warren CM, Li J, McKinsey TA, Russell B. Myofibril growth during cardiac hypertrophy is regulated through dual phosphorylation and acetylation of the actin capping protein CapZ. Cell Signal. 2016 08; 28(8):1015-24.
Score: 0.129
-
Stauffer BL, Dockstader K, Russell G, Hijmans J, Walker L, Cecil M, Demos-Davies K, Medway A, McKinsey TA, Sucharov CC. Transgenic over-expression of YY1 induces pathologic cardiac hypertrophy in a sex-specific manner. Biochem Biophys Res Commun. 2015 Jun 26; 462(2):131-7.
Score: 0.120
-
Pedram A, Razandi M, Narayanan R, Dalton JT, McKinsey TA, Levin ER. Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell. 2013 Dec; 24(24):3805-18.
Score: 0.108
-
Bush EW, McKinsey TA. Targeting histone deacetylases for heart failure. Expert Opin Ther Targets. 2009 Jul; 13(7):767-84.
Score: 0.080
-
Sucharov CC, Dockstader K, McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell. 2008 Oct; 19(10):4141-53.
Score: 0.075
-
Bush E, Fielitz J, Melvin L, Martinez-Arnold M, McKinsey TA, Plichta R, Olson EN. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2870-5.
Score: 0.055
-
Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem. 2003 Aug 01; 278(31):28930-7.
Score: 0.052
-
McKinsey TA, Zhang CL, Olson EN. Signaling chromatin to make muscle. Curr Opin Cell Biol. 2002 Dec; 14(6):763-72.
Score: 0.051
-
Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):907-12.
Score: 0.048
-
Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant SR, Olson EN. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest. 2000 May; 105(10):1395-406.
Score: 0.042
-
Meredith EL, Ardayfio O, Beattie K, Dobler MR, Enyedy I, Gaul C, Hosagrahara V, Jewell C, Koch K, Lee W, Lehmann H, McKinsey TA, Miranda K, Pagratis N, Pancost M, Patnaik A, Phan D, Plato C, Qian M, Rajaraman V, Rao C, Rozhitskaya O, Ruppen T, Shi J, Siska SJ, Springer C, van Eis M, Vega RB, von Matt A, Yang L, Yoon T, Zhang JH, Zhu N, Monovich LG. Identification of orally available naphthyridine protein kinase D inhibitors. J Med Chem. 2010 Aug 12; 53(15):5400-21.
Score: 0.022
-
Meredith EL, Beattie K, Burgis R, Capparelli M, Chapo J, Dipietro L, Gamber G, Enyedy I, Hood DB, Hosagrahara V, Jewell C, Koch KA, Lee W, Lemon DD, McKinsey TA, Miranda K, Pagratis N, Phan D, Plato C, Rao C, Rozhitskaya O, Soldermann N, Springer C, van Eis M, Vega RB, Yan W, Zhu Q, Monovich LG. Identification of potent and selective amidobipyridyl inhibitors of protein kinase D. J Med Chem. 2010 Aug 12; 53(15):5422-38.
Score: 0.022
-
Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004 Oct; 24(19):8467-76.
Score: 0.014
-
Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med. 2000 Nov; 6(11):1221-7.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|